Abivax (ABVX) Income from Continuing Operations (2024 - 2026)
Abivax (ABVX) recorded quarterly Income from Continuing Operations of 56476770.16 in Q1 2026, up 36.29% quarter-over-quarter from 88651225.99 in Q4 2025, and down 2.52% on a YoY basis from 57938271.19 in Q1 2025.
Abivax (ABVX) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Abivax's Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 56476770.16 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 2.52% year-over-year to 56476770.16; the TTM figure through Mar 2026 stood at 379214643.19 (down 90.06% YoY), while the FY2025 annual figure was 391290899.38, down 107.82% from the prior year.
- Income from Continuing Operations was 56476770.16 for Q1 2026 at Abivax, up from 88651225.99 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 41750931.33 in Q2 2024 to a low of 179283950.7 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 69478607.74 across 3 years, with a median of 55087188.1 in 2025.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations slumped 195.6% in 2025, then retreated 2.52% in 2026.
- A 3-year view of Income from Continuing Operations shows it stood at 42034268.66 in 2024, then slumped by 110.9% to 88651225.99 in 2025, then soared by 36.29% to 56476770.16 in 2026.
- The last three Income from Continuing Operations figures came in at 56476770.16 (Q1 2026), 88651225.99 (Q4 2025), and 179283950.7 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 727.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.48 Mn |
| Dec 31, 2025 | -88.65 Mn |
| Sep 30, 2025 | -179.28 Mn |
| Jun 30, 2025 | -54.80 Mn |
| Mar 31, 2025 | -55.09 Mn |
| Dec 31, 2024 | -42.03 Mn |
| Sep 30, 2024 | -60.65 Mn |
| Jun 30, 2024 | -41.75 Mn |
| Mar 31, 2024 | -46.57 Mn |